Ahead of a PDUFA date or a data readout, see how many specialists own the stock and whether that rose or fell last quarter.
12 or more funds is a crowded trade; one or two means ask why. Thin specialist ownership is the clearest warning in our data.
Funds Δ and Shares QoQ show where specialists are building and where they are leaving. New positions say more than dollar changes.
Fewer funds and fewer shares while the price rose can mean specialists sold into strength. Each fund's own page shows who sold.
| Rank | Stock | company Name | Hedge Funds | Last 4 Quarters | Funds Δ | Next Catalyst | Stocks Held | Shares QoQ | Market value | QoQ Change | Quarter | Option Holders |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | TVTX | Travere Therapeutics, Inc. | 7 | 9 › 7 | Oct 22, 2026 Pre-clinical data presentation | 7.97 M | 452.82 M | Q2 2026 | 0 |
Hedge Funds counts each fund once, by its stock positions (Holders: share holders). Set Holders to option holders to see the funds holding calls or puts. QoQ Change is the stock's price move between the two 13F filing dates. Each fund's own page lists everything it holds.
In Q2 2026, RVMD was held by 19 of the 45 specialist funds we track, the most of any stock. The Hedge Funds column ranks every stock the same way.
45 biotech and healthcare specialists, such as RA Capital, Baker Bros., Perceptive, OrbiMed and Deep Track. Each has its own holdings page.
We count funds that own shares. Funds holding only options are shown with the Holders filter, and we track 45 specialists rather than every institution.
After each quarterly 13F deadline, 45 days after quarter end. Q3 2026 filings are due Nov 16, 2026.
Source: SEC EDGAR Form 13F-HR filings of 45 specialist biotech funds. Stock positions by default; option positions counted apart.